- Home
- PRLD vs CGTX Comparison
PRLD vs CGTX Comparison
Compare PRLD & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- CGTX
- Stock Information
- Founded
- PRLD 2016
- CGTX 2007
- Country
- PRLD United States
- CGTX United States
- Employees
- PRLD N/A
- CGTX N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- CGTX Health Care
- Exchange
- PRLD Nasdaq
- CGTX Nasdaq
- Market Cap
- PRLD 48.6M
- CGTX 53.4M
- IPO Year
- PRLD 2020
- CGTX 2021
- Fundamental
- Price
- PRLD $0.82
- CGTX $0.60
- Analyst Decision
- PRLD Strong Buy
- CGTX Strong Buy
- Analyst Count
- PRLD 2
- CGTX 4
- Target Price
- PRLD $4.50
- CGTX $2.83
- AVG Volume (30 Days)
- PRLD 121.2K
- CGTX 20.1M
- Earning Date
- PRLD 08-11-2025
- CGTX 08-07-2025
- Dividend Yield
- PRLD N/A
- CGTX N/A
- EPS Growth
- PRLD N/A
- CGTX N/A
- EPS
- PRLD N/A
- CGTX N/A
- Revenue
- PRLD $7,000,000.00
- CGTX N/A
- Revenue This Year
- PRLD N/A
- CGTX N/A
- Revenue Next Year
- PRLD N/A
- CGTX N/A
- P/E Ratio
- PRLD N/A
- CGTX N/A
- Revenue Growth
- PRLD N/A
- CGTX N/A
- 52 Week Low
- PRLD $0.61
- CGTX $0.22
- 52 Week High
- PRLD $6.80
- CGTX $1.29
- Technical
- Relative Strength Index (RSI)
- PRLD 44.66
- CGTX 49.83
- Support Level
- PRLD $0.81
- CGTX $0.62
- Resistance Level
- PRLD $1.00
- CGTX $0.87
- Average True Range (ATR)
- PRLD 0.08
- CGTX 0.08
- MACD
- PRLD 0.00
- CGTX -0.02
- Stochastic Oscillator
- PRLD 20.48
- CGTX 11.67
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.